The Effect of Using Transcutaneous Electrical Nerve Stimulation on the Severity of Pain, Nausea and Vomiting after Percutaneous Nephrolithotomy

The Effect of Using High Transcutaneous Electrical Nerve Stimulation (TENS) on the Severity of Pain, Nausea and Vomiting after Percutaneous Nephrolithotomy (PCNL)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016112030989N1

Enrollment

Registered

2017-01-25

Start date

2016-10-31

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery for kidney stones. Calculus of kidney

Interventions

Intervention 1: Intervention group: After surgery, in the intervention group TENS with a frequency of 100 Hz, based on patient tolerance at a distance of 5 cm from the nephrostomy for 20 minutes twice

Placebo

Intervention group: After surgery, in the intervention group TENS with a frequency of 100 Hz, based on patient tolerance at a distance of 5 cm from the nephrostomy for 20 minutes twice with an interva

In the placebo group TENS unit is turned on, but with zero intensity and frequency i.e. no electrical stimulation. The severity of pain, nausea and vomiting before and after the placebo TENS to be mea

In the control group, no intervention is applied. The severity of pain, nausea and vomiting before and after surgery to be measured for 12 hours.

Eligibility

Sex/Gender

All

Age

15 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: The patients who have 15-70 age old; All of consciousness patients who have unilateral percutaneous nephrolithotomy surgery; Ability to speak and understand the Persian language. Exclusion criteria: Those due to uncontrollable nausea and vomiting may require medication; The incidence of adverse events recorded in the patient during surgery; Drug addiction; Being blind; The patients with motion sickness; Digestive disorders associated with nausea and vomiting; Mental retardation or mental disorders and epilepsy; Pregnancy; Patients who have cardiac pacemaker.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: Before the intervention, immediately after intervention, 1, 2, 6 and 12 hours after intervention. Method of measurement: 11–point Numeric Rating Scale.;Nausea. Timepoint: Before the intervention, immediately after intervention, 1, 2, 6 and 12 hours after intervention. Method of measurement: Visual Analog Scale.;Vomiting. Timepoint: After receiving TENS to 12 hours being counted. Method of measurement: The vomiting and retching frequency form.	—

Measure

Time frame

Pain. Timepoint: Before the intervention, immediately after intervention, 1, 2, 6 and 12 hours after intervention. Method of measurement: 11–point Numeric Rating Scale.;Nausea. Timepoint: Before the intervention, immediately after intervention, 1, 2, 6 and 12 hours after intervention. Method of measurement: Visual Analog Scale.;Vomiting. Timepoint: After receiving TENS to 12 hours being counted. Method of measurement: The vomiting and retching frequency form.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRadnoush Shadmehri

Sabzevar University of Medical Sciences

shadmehrir1@mums.ac.ir+98 51 4401 1300

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026